Journal
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 53, Issue 2, Pages 152-157Publisher
ELSEVIER
DOI: 10.1016/j.ijantimicag.2018.10.010
Keywords
Polymyxin B; Klebsiella pneumoniae; Mortality; beta-Lactamase; Carbapenem; Amikacin
Funding
- 'Fundo de Incentivo a Pesquisa e Eventos do Hospital de Clinicas de Porto Alegre' from Hospital de Clinicas de Porto Alegre (Porto Alegre, Brazil) [15-0642]
Ask authors/readers for more resources
Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) bloodstream infections (BSIs) are related to high mortality rates, and combination therapy has been associated with lower mortality in patients treated mostly with colistin. There is a paucity of studies addressing polymyxin B (PMB) treatment for KPC-KP infections. This was a retrospective cohort study of patients with monomicrobial KPC-KP BSIs. The primary outcome was 30-day mortality. Antimicrobial therapy was defined as empirical (started within the first 48 h) or definitive (initiated after >48 h) and was evaluated as follows: monotherapy (only one in vitro active agent or combination therapy of one in vitro active agent plus one or more in vitro non-active agents); and combination therapy with two or more in vitro active agents. A total of 82 KPC-KP BSIs were included; 40 patients (48.8%) died in the first 30 days. Mortality of patients treated with the combination of two in vitro active antimicrobial agents, mostly PMB plus amikacin, was significantly lower (37.5%) compared with monotherapy (64.7%) (P = 0.01). Combination therapy [ adjusted hazard ratio (aHR) = 0.40, 95% confidence interval (CI) 0.22-0.83; P = 0.01] was independently associated with lower 30-day survival when controlled for non-surgical admission (aHR = 2.33, 95% CI 1.14-4.80; P = 0.02) and use of vasoactive drugs (aHR = 7.37, 95% CI 3.01-18.02; P < 0.01). In conclusion, combination therapy with two in vitro active agents, mostly PMB plus amikacin, showed a survival benefit compared with other regimens. (c) 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available